March 27, 2018 / 2:47 PM / 4 months ago

BRIEF-Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan

March 27 (Reuters) - Merck KGaA:

* MERCK RECEIVES FAST-TRACK DESIGNATION FOR TEPOTINIB IN NON-SMALL CELL LUNG CANCER IN JAPAN

* MERCK KGAA - SAKIGAKE DESIGNATION ENCOMPASSES POSSIBILITY FOR A TARGET REVIEW PERIOD OF 6 MONTHS

* MERCK KGAA - JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS SAKIGAKE DESIGNATION FOR TEPOTINIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below